A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease - GATEWAY clinical trial

Vivet Therapeutics SAS0 个研究点目标入组 16 人开始时间: 2021年3月10日最近更新: 2024年4月22日

试验速览

暂无简介。

•1. Male or female aged 18-65 years old (inclusive)
•2. Confirmed diagnosis of WD
•3. Treated for WD according to international recommendations with no current evidence for inadequate treatment (EASL, 2012; Roberts et al, 2008)
•4. Stable WD for = 1 year, defined as: (i) No significant change in neurologic examination and in status of mood disorder, and (ii) stable laboratory parameters used to assess copper metabolism including 24-hour urinary copper, free serum copper such as NCC or CuEXC (when available), as well as liver enzymes, hemoglobin, and white blood cell count
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 16
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. ALT level = 2 x ULN that is not readily explained by extrinsic factors (e.g., strenuous exercise, medication use)
•2. Total bilirubin > 1.5 x ULN in the absence of proven Gilbert's
•syndrome; in case of Gilbert's syndrome, direct bilirubin > ULN
•3. Platelet count < 120.000 / µL
•4. Any signs of liver cirrhosis decompensation, including gastrointestinal
•bleed within 6 months (24 weeks) prior to screening/enrolment visit
•5. Patient has moderate or severe renal impairment or patient has
•nephritis or nephrotic syndrome
•6. Any history or current evidence of HIV-1, HIV-2, HTLV 1, or HTLV-2 infection
•7. Any history or current evidence of hepatitis B infection
•8. Any history of hepatitis C infection, unless previous viral RNA assays
•in two samples, collected at least 6 months apart, are negative
•9. Positive QuantiFERON®-TB Gold tuberculosis test result
•10. Any concomitant disorder/condition - including hepatic disorders - or
•treatment possibly interfering with the conduct or evaluation of the
•study, according to the Investigator
•11. Pregnancy or breastfeeding
•12. Body Mass Index = 35 kg/m2

发起方